Effects of inhaled beclomethasone dipropionate on serum IgE levels and clinical symptoms in atopic asthma
Article first published online: 24 DEC 2001
Clinical & Experimental Allergy
Volume 29, Issue 3, pages 357–361, March 1999
How to Cite
Ohrui, Funayama, Sekizawa, Yamaya and Sasaki (1999), Effects of inhaled beclomethasone dipropionate on serum IgE levels and clinical symptoms in atopic asthma. Clinical & Experimental Allergy, 29: 357–361. doi: 10.1046/j.1365-2222.1999.00474.x
- Issue published online: 24 DEC 2001
- Article first published online: 24 DEC 2001
- allergic reaction;
- skin-prick test
A high serum immunoglobulin (Ig)E level is considered a potent predictor for the development of asthma and IgE is targeted for treatment of asthma. Although inhaled corticosteroids are well established in the treatment of asthma, the effects of inhaled corticosteroids on serum IgE levels in asthma remain uncertain.
We therefore examined asthma symptoms, concentrations of total serum IgE and specific IgE antibodies to selected allergens, blood eosinophil counts and lung functions before and 3 months after treatment with either inhaled beclomethasone dipropionate (BDP; 800 μg/day) (n = 7) or inhaled β2-agonists alone (n = 7) in patients with atopic asthma in a randomized, double-blind, parallel-group controlled trial.
Inhaled BDP significantly improved asthma symptom scores and forced expiratory volume in 1 s, and decreased blood eosinophil counts, total serum IgE levels and specific IgE antibodies to house dust mite and cedar. Decreases in total serum IgE significantly correlated with an improvement in asthma symptom scores. In contrast, none of parameters altered in patients with atopic asthma treated with inhaled β2-agonists alone.
Inhaled corticosteroids may improve the subsequent clinical course of atopic asthma in association with a reduction of serum IgE levels.